JP Stock MarketDetailed Quotes

4502 Takeda Pharmaceutical

Watchlist
  • 4220.0
  • +69.0+1.66%
20min DelayNoon Break Feb 17 11:30 JST
6.71TMarket Cap46.29P/E (Static)

About Takeda Pharmaceutical Company

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Company Profile

Symbol4502
Company NameTakeda Pharmaceutical
Founded1925-01-29
MarketTSE Prime
Employees49281
Fiscal Year Ends03-31
Address1-1, Nihonbashi-Honcho 2-Chome Chuo-ku
Zip Code540-8645
Phone06-6204-2111

Company Executives

  • Name
  • Position
  • Salary
  • Akiko Amakawa
  • Corporate Strategy Officer and Chief Executive Officer Chief of Staff
  • --
  • Christophe Weber
  • Director, President and Chief Executive Officer; Head of Global Business of Takeda Pharmaceuticals U.S.a., Inc.
  • 1.70B
  • Mwana Lugogo
  • Chief Ethics and Compliance Officer
  • --
  • Milano Furuta
  • Director and Chief Financial Officer
  • --
  • Lauren Duprey
  • Chief Human Resources Officer
  • --
  • Takako Ohyabu
  • Chief Global Corporate Affairs and Sustainability Officer
  • --
  • Gabriele Ricci
  • Chief Data and Technology Officer
  • --
  • Marcello Agosti
  • Global Business Development Officer
  • --
  • Dr. Thomas Wozniewski, PhD
  • Global Manufacturing and Supply Officer
  • --
  • Elaine Shannon
  • Global Quality Officer
  • --
  • Ramona Sequeira
  • President, Global Portfolio Division
  • --
  • Teresa Marie Bitetti
  • President, Global Oncology Business Unit
  • --
  • Giles Platford
  • President, Plasma-Derived Therapies Business Unit
  • --
  • Asuka Miyabashira
  • President, Japan Pharma Business Unit
  • --
  • Andrew S. Plump, M.D.
  • Director and President, Research and Development
  • 12.00M
  • Julie Kim
  • President, U.S. Business Unit and U.S. Country Head
  • --
  • Masami Iijima
  • Chairman of the Board
  • 43.00M
  • Dr. Steven Gillis, Pd.D
  • Independent Director
  • 44.00M
  • Dr. John M. Maraganore,PhD
  • Independent Director
  • 39.00M
  • Miki Tsusaka
  • Independent Director
  • 32.00M
  • Emiko Higashi
  • Independent Director
  • 49.00M
  • Kimberly A. Reed
  • Independent Director
  • 41.00M
  • Jean-Luc Butel
  • Independent Director
  • 38.00M
  • Ian T. Clark
  • Independent Director
  • 44.00M
  • Yoshiaki Fujimori
  • Independent Director
  • 40.00M
  • Michel Orsinger
  • Independent Director
  • 46.00M
  • Koji Hatsukawa
  • Independent Director
  • 43.00M
  • Yoshihiro Nakagawa
  • Global General Counsel
  • --